Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre

Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre

Background: Metastatic renal cell carcinoma is chemoresistant and radioresistant disease with poor survival historically, but outcome has improved in past decade after introduction of tyrosine kinase inhibitors like sunitinib and sorafenib. Sorafenib has not been tested in Indian patients with metas...

Full description

Bibliographic Details
Main Authors: Mohit Saxena, Irappa Madabhavi, Apurva Patel, Harsha Panchal, Asha Anand
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2018-07-01
Series:International Journal of Hematology-Oncology and Stem Cell Research
Subjects:
Renal cell carcinoma
Sorafenib
Metastatic
First line
Online Access:https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/684

Similar Items

Similar Items